antibody-based molecular imaging agent gives hope for new treatments against breast cancer -
houses of molecular imaging agents based antibodies in the newly targeted cellular receptor that alludes to more aggressive breast and potential therapy
for years, researchers have developed molecular imaging techniques to visualize cells specifically cancer the hormone-active testing positive for the receptor of the human epidermal growth factor 2 (HER2). A recent innovation in breast cancer biomarker HER3 receptor seeks instead, which could mean imaging fuller breast cancer and potential treatments, experts say presenting data during the Society of Nuclear Medicine and 2014 annual Meeting of the molecular imaging.
Breast cancer is one of the most common forms of cancer in women. Certain types of tumors have been found to be more aggressive and associated with less favorable prognosis compared to others. HER2 positive tumors are a characteristic of breast cancer in high risk. Emerging molecular imaging agents join the antibody tumor research and signaling radioisotopes in a radiopharmaceutical is injected at the time of imaging to track and report the active receivers.
One of these experimental agents, known in the laboratory as Cu-DOTA HER3 -64 F (ab ') 2, comes only through hunting HER3, a messenger was shown talking to HER2-positive cancer in multiple tissues models when used in conjunction with a scanner called a positron emission tomography (PET), the imaging system. This might encourage better care, more personalized for patients with breast cancer.
"HER3 is considered an important mediator of resistance to HER2 inhibitor class of anti-cancer therapies, which are used to treat HER2-positive breast cancer accounts for about 20 percent of all cancers breast, "said lead author Eric P. Wehrenberg-Klee, MD, of Massachusetts General Hospital in Boston, Mass." Imaging of HER3 expression may provide a better understanding of how widespread HER3 over-expression is from patients with HER2 positive breast cancer, which in turn can allow the selection of appropriate patients for the addition of HER3 inhibitors currently in development clinic. "
researchers expect that it may be a year or two before the agent reaches regulatory approval and enter general clinical practice.
an estimated 232.670 new cases of invasive breast cancer will be diagnosed in women this year, according to the 2014 American cancer Society data. Approximately 40,000 women will die from breast cancer this year.
EmoticonEmoticon